Dear Dr. Baylor:

Please refer to your Biologics License Application (BLA) submitted and received November 30, 2020, under section 351(a) of the Public Health Service Act (PHS Act) for Hepatitis B Vaccine (Recombinant).

**LICENSING**

We are issuing Department of Health and Human Services U.S. License No. 2219 to VBI Vaccines (Delaware) Inc., Cambridge, MA, under the provisions of section 351(a) of the PHS Act controlling the manufacture and sale of biological products. The license authorizes you to introduce or deliver for introduction into interstate commerce, those products for which your company has demonstrated compliance with establishment and product standards.

Under this license, you are authorized to manufacture the product Hepatitis B Vaccine (Recombinant), which is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years and older.

The review of this product was associated with the following National Clinical Trial (NCT) numbers: NCT03393754 and NCT03408730.

**MANUFACTURING LOCATIONS**

Under this license, you are approved to manufacture Hepatitis B Vaccine (Recombinant) drug substance and drug product at SciVac Ltd., a subsidiary of VBI Vaccines (Delaware) Inc., located in Rehovot, Israel. You may label your product with the proprietary name PREHEVBRIO and market it in glass vials, containing a single 1.0 mL dose of vaccine, in packages of 10 vials.
We did not refer your application to the Vaccines and Related Biological Products Advisory Committee because our review of information submitted in your BLA, including the clinical study design and trial results, did not raise concerns or controversial issues that would have benefited from an advisory committee discussion.

**DATING PERIOD**

The dating period for Hepatitis B Vaccine (Recombinant) shall be 36 months from the date of manufacture when stored at 2 - 8 °C. The date of manufacture shall be defined as the date of initiation of filling of the drug product into final containers. Following the final sterile filtration, no reprocessing/reworking is allowed without prior approval from the Agency. The dating period for your drug substance shall be months when stored at (b) (4)

**FDA LOT RELEASE**

Please submit final container samples of the product in final containers together with protocols showing results of all applicable tests. You may not distribute any lots of product until you receive a notification of release from the Director, Center for Biologics Evaluation and Research (CBER).

**BIOLOGICAL PRODUCT DEVIATIONS**

You must submit reports of biological product deviations under 21 CFR 600.14. You should identify and investigate all manufacturing deviations promptly, including those associated with processing, testing, packaging, labeling, storage, holding and distribution. If the deviation involves a distributed product, may affect the safety, purity, or potency of the product, and meets the other criteria in the regulation, you must submit a report on Form FDA 3486 to the Director, Office of Compliance and Biologics Quality, electronically through the eBPDR web application or at the address below.

Links for the instructions on completing the electronic form (eBPDR) may be found on CBER's web site at https://www.fda.gov/vaccines-blood-biologics/report-problem-center-biologics-evaluation-research/biological-product-deviations:

Food and Drug Administration  
Center for Biologics Evaluation and Research  
Document Control Center  
10903 New Hampshire Ave.  
WO71-G112  
Silver Spring, MD 20993-0002
MANUFACTURING CHANGES

You must submit information to your BLA for our review and written approval under 21 CFR 601.12 for any changes in, including but not limited to, the manufacturing, testing, packaging or labeling of Hepatitis B Vaccine (Recombinant), or in the manufacturing facilities.

LABELING

We hereby approve the draft content of labeling including Package Insert, submitted under amendment 44, dated November 30, 2021 and the draft carton and container labels submitted under amendment 40, dated November 23, 2021.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, please submit the final content of labeling (21 CFR 601.14) in Structured Product Labeling (SPL) format via the FDA automated drug registration and listing system, (eLIST) as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the Package Insert submitted on November 30, 2021. Information on submitting SPL files using eLIST may be found in the guidance for industry SPL Standard for Content of Labeling Technical Qs and As at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible via publicly available labeling repositories.

CARTON AND CONTAINER LABELS


All final labeling should be submitted as Product Correspondence to this BLA, STN BL 125737 at the time of use and include implementation information on Form FDA 356h.

ADVERTISING AND PROMOTIONAL LABELING

You may submit two draft copies of the proposed introductory advertising and promotional labeling with Form FDA 2253 to the Advertising and Promotional Labeling Branch at the following address:
You must submit copies of your final advertising and promotional labeling at the time of initial dissemination or publication, accompanied by Form FDA 2253 (21 CFR 601.12(f)(4)).

All promotional claims must be consistent with and not contrary to approved labeling. You should not make a comparative promotional claim or claim of superiority over other products unless you have substantial evidence or substantial clinical experience to support such claims (21 CFR 202.1(e)(6)).

ADVERSE EVENT REPORTING

You must submit adverse experience reports in accordance with the adverse experience reporting requirements for licensed biological products (21 CFR 600.80), and you must submit distribution reports as described in 21 CFR 600.81. For information on adverse experience reporting, please refer to the guidance for industry Providing Submissions in Electronic Format — Postmarketing Safety Reports for Vaccines at [http://www.fda.gov/forindustry/electronicsubmissionsgateway/ucm387293.htm](http://www.fda.gov/forindustry/electronicsubmissionsgateway/ucm387293.htm). For information on distribution reporting, please refer to the guidance for industry Electronic Submission of Lot Distribution Reports at [http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Post-MarketActivities/LotReleases/ucm061966.htm](http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Post-MarketActivities/LotReleases/ucm061966.htm).

PEDIATRIC REQUIREMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study requirement for this application because this product does not represent a meaningful therapeutic benefit over existing therapies for pediatric patients and is not likely to be used in a substantial number of pediatric patients.

POSTMARKETING COMMITMENTS SUBJECT TO REPORTING REQUIREMENTS UNDER SECTION 506B

We acknowledge your written commitment as described in your letter of November 9, 2021 as outlined below:
1. To establish a pregnancy registry to prospectively collect data on reported
exposures to PREHEVBRI0 during pregnancy and evaluate pregnancy
outcomes. The registry will collect information from 120 pregnant women.

   Final protocol submission: February 1, 2022
   Study/Clinical trial completion: March 1, 2032
   Final Report Submission: December 1, 2032

Please submit clinical protocols to your IND 17542, and a cross-reference letter to this
BLA, STN BL 125737, explaining that this protocol was submitted to the IND.

If the information in the final study report supports a change in the label, the final study
report must be submitted as a supplement. Please use the following designators to
prominently label all submissions, including supplements, relating to these
postmarketing study commitments as appropriate:

- **Postmarketing Commitment – Correspondence**
- **Postmarketing Commitment – Final Study Report**
- **Supplement contains Postmarketing Commitment – Final Study Report**

For each postmarketing study subject to the reporting requirements of 21 CFR 601.70,
you must describe the status in an annual report on postmarketing studies for this
product. Label your annual report as an **Annual Status Report of Postmarketing
Requirements/Commitments** and submit it to the FDA each year within 60 calendar
days of the anniversary date of this letter until all Requirements and Commitments
subject to the reporting requirements of section 506B of the FDCA are fulfilled or
released. The status report for each study should include:

- the sequential number for each study as shown in this letter;
- information to identify and describe the postmarketing commitment;
- the original schedule for the commitment;
- the status of the commitment (i.e., pending, ongoing, delayed, terminated, or
  submitted); and,
- an explanation of the status including, for clinical studies, the patient accrual rate
  (i.e., number enrolled to date and the total planned enrollment).

As described in 21 CFR 601.70(e), we may publicly disclose information regarding
these postmarketing studies on our website at [http://www.fda.gov/Drugs/Guidance
ComplianceRegulatoryInformation/Post-marketingPhaseIVCommitments/default.htm](http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Post-marketingPhaseIVCommitments/default.htm).
POST APPROVAL FEEDBACK MEETING

New biological products qualify for a post approval feedback meeting. Such meetings are used to discuss the quality of the application and to evaluate the communication process during drug development and marketing application review. The purpose is to learn from successful aspects of the review process and to identify areas that could benefit from improvement. If you would like to have such a meeting with us, please contact the Regulatory Project Manager for this application.

Sincerely,

Anita F. Richardson, for
Mary A. Malarkey
Director
Office of Compliance and Biologics Quality
Center for Biologics
Evaluation and Research

Peter Marks
Acting Director
Office of Vaccines
Research and Review
Center for Biologics
Evaluation and Research